GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » EV Biologics Inc (OTCPK:YECO) » Definitions » Notes Receivable

EV Biologics (EV Biologics) Notes Receivable : $0.00 Mil (As of Dec. 2017)


View and export this data going back to 2015. Start your Free Trial

What is EV Biologics Notes Receivable?

EV Biologics's Notes Receivable for the quarter that ended in Dec. 2017 was $0.00 Mil.


EV Biologics Notes Receivable Historical Data

The historical data trend for EV Biologics's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

EV Biologics Notes Receivable Chart

EV Biologics Annual Data
Trend Jun13 Jun14 Jun15 Jun16 Jun17
Notes Receivable
- - - - -

EV Biologics Quarterly Data
Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Jun17 Dec17
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

EV Biologics Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.


EV Biologics Notes Receivable Related Terms

Thank you for viewing the detailed overview of EV Biologics's Notes Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


EV Biologics (EV Biologics) Business Description

Traded in Other Exchanges
N/A
Address
1621 Central Avenue, Cheyenne, WY, USA, 82001
EV Biologics Inc is developing the extraordinary biological properties of extracellular vesicles (EVs) to create the next generation of diagnostic modalities and safe, effective biotherapeutics to improve outcomes of serious clinical conditions, increase natural longevity and transform lives.
Executives
Daniel S Mckinney director, 10 percent owner, officer: CEO TWO IFC, 19TH FLOOR, 8 FINANCE STREET, CENTRAL, HONG KONG F4 000000
Michael W Harlan director C/O WASTE CONNECTIONS, INC., 610 APPLEWOOD CRESCENT, SUITE 200, VAUGHAN A6 L4K 0C3

EV Biologics (EV Biologics) Headlines

From GuruFocus

EV Biologics Unveils NFT Dividend Warrant

By ACCESSWIRE ACCESSWIRE 07-26-2021

EV Biologics Updates on FINRA

By ACCESSWIRE ACCESSWIRE 01-18-2022

EV Biologics Updates on Funding and Sales

By ACCESSWIRE 10-02-2023

EV Biologics Generates Mesenchymal Stem Cell Lines

By ACCESSWIRE ACCESSWIRE 02-21-2023

EV Biologics Updates Shareholders on Name and Symbol Change

By ACCESSWIRE ACCESSWIRE 05-19-2021

EV Biologics Announces NFT Dividend

By ACCESSWIRE ACCESSWIRE 07-14-2021

EV Biologics Updates on NFT Minting

By ACCESSWIRE ACCESSWIRE 09-28-2021

EV Biologics Signs LOI with Lonza Cell & Gene Therapy

By ACCESSWIRE ACCESSWIRE 07-22-2021

EV Biologics Updates on FINRA Filings

By ACCESSWIRE ACCESSWIRE 03-09-2022